Related Experiment Video
Updated: Jul 26, 2026
06:53
Cell Population Analyses During Skin Carcinogenesis
Published on: August 21, 2013
Development of a core outcome set for basal cell carcinoma
Daniel I Schlessinger1, Kelly A Reynolds2, McKenzie A Dirr3
1Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Division of Dermatology, Department of Internal Medicine, Washington University, St. Louis, Missouri.
Journal of the American Academy of Dermatology
|May 13, 2022
Summary
A core outcome set for basal cell carcinoma (BCC) trials was developed. This aims to improve clinical research consistency and therapeutic guidance for BCC patients.
Area of Science:
- Dermatology
- Clinical Trials Methodology
- Oncology
Background:
- Variability in reported outcomes in basal cell carcinoma (BCC) studies hinders meta-analyses.
- This inconsistency impacts the ability to answer critical clinical questions regarding BCC management.
Purpose of the Study:
- To establish a minimum set of core outcomes for basal cell carcinoma clinical trials.
- Standardizing outcome reporting to enhance research comparability and clinical decision-making.
Main Methods:
- A Delphi process involving patients and healthcare professionals was employed.
- Outcomes were rated for importance, requiring 70% consensus from each stakeholder group for provisional acceptance.
Main Results:
- An initial 235 outcomes were narrowed to 74, then 27, and finally 5 core outcomes.
- The final core set includes complete response, adverse events, recurrence-free survival, quality of life, and patient satisfaction (including cosmetic outcome).
Conclusions:
- A standardized core outcome set for basal cell carcinoma has been established.
- Implementation of this set is expected to improve the utility of clinical research and therapeutic guidance for clinicians.
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:19Clinical Applications of Epidermal Stem Cells
2.8K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.8K
01:30Skin Cancer
4.7K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.7K
01:22Standards of Care I
767
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
767
01:19Standards of Care II
732
Nurses bear specific legal responsibilities under several federal statutes, including:
732
01:21Cancer Survival Analysis
470
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
470